Final Report of a Phase II Trial of Nimotuzumab in the Treatment of Refractory and Relapsed High-Grade Gliomas in Children and Adolescents. Hematol Meeting Rep 2009, 1 (6). https://doi.org/10.4081/hmr.v1i6.675.